Rapastinel

Generic Name: Rapastinel

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₁N_₅O_₆

CAS Number: 117928-94-6

Unique Ingredient Identifier: 6A1X56B95E

Background: Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cybin's Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom

Cybin's CYB003, a deuterated psilocin drug for MDD, showed 12-month efficacy with 100% response rate and 71% sustained remission. The FDA's Breakthrough Therapy Designation supports its potential over existing therapies, with no new adverse events reported. Cybin plans to launch Phase 3 PARADIGM program for global efficacy and safety assessment.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy